Cargando…
Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body
BACKGROUND: Fabry disease is caused by mutations in the α-galactosidase A (GLA) gene, which is located in X-chromosome coding for the lysosomal enzyme of GLA. Among many gene mutations, E66Q mutation is under discussion for its pathogenicity because there is no clinical report showing pathological e...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862085/ https://www.ncbi.nlm.nih.gov/pubmed/27160240 http://dx.doi.org/10.1186/s12872-016-0262-y |
_version_ | 1782431305704669184 |
---|---|
author | Oikawa, Masayoshi Sakamoto, Nobuo Kobayashi, Atsushi Suzuki, Satoshi Yoshihisa, Akiomi Yamaki, Takayoshi Nakazato, Kazuhiko Suzuki, Hitoshi Saitoh, Shu-ichi Kiko, Yuichirou Nakano, Hajime Hayashi, Takeharu Kimura, Akinori Takeishi, Yasuchika |
author_facet | Oikawa, Masayoshi Sakamoto, Nobuo Kobayashi, Atsushi Suzuki, Satoshi Yoshihisa, Akiomi Yamaki, Takayoshi Nakazato, Kazuhiko Suzuki, Hitoshi Saitoh, Shu-ichi Kiko, Yuichirou Nakano, Hajime Hayashi, Takeharu Kimura, Akinori Takeishi, Yasuchika |
author_sort | Oikawa, Masayoshi |
collection | PubMed |
description | BACKGROUND: Fabry disease is caused by mutations in the α-galactosidase A (GLA) gene, which is located in X-chromosome coding for the lysosomal enzyme of GLA. Among many gene mutations, E66Q mutation is under discussion for its pathogenicity because there is no clinical report showing pathological evidence of Fabry disease with E66Q mutation. CASE PRESENTATION: A 65-year-old Japanese female was referred to our hospital for chest discomfort on effort. Transthoracic echocardiography showed severe left ventricular (LV) hypertrophy with LV outflow obstruction. Maximum LV outflow pressure gradient was 87 mmHg, and Valsalva maneuver increased the pressure gradient up to 98 mmHg. According to medical interview, one of her younger sister and a nephew died suddenly at age 42 and 36, respectively. Another younger sister also presented LV hypertrophy with outflow obstruction. Maximum LV outflow pressure gradient was 100 mmHg, and the E66Q mutation was detected similar to the case. Endomyocardial biopsy specimens presented vacuolation of cardiomyocytes, in which zebra bodies were detected by electron microscopic examination. Although the enzymatic activity of GLA was within normal range, the c. 196G>C nucleotide change, which lead to the E66Q mutation of GLA gene, was detected. We initially diagnosed her as cardiac Fabry disease based on the findings of zebra body. However, immunostaining showed few deposition of globotriaosylceramide in left ventricular myocardium, and gene mutations in the disease genes for hypertrophic cardiomyopathy (HCM), MYBPC3 and MYH6, were detected. Although the pathogenicity of the E66Q mutation cannot be ruled out, hypertrophic obstructive cardiomyopathy (HOCM) was more reasonable to explain the pathophysiology in the case. CONCLUSIONS: This is the confusable case of HOCM with Fabry disease with the GLA E66Q mutation. We have to take into consideration the possibility that some patients with the E66Q mutation may have similar histological findings of Fabry disease, and should be examed the possibility for harboring gene mutations associated with HCM. |
format | Online Article Text |
id | pubmed-4862085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48620852016-05-11 Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body Oikawa, Masayoshi Sakamoto, Nobuo Kobayashi, Atsushi Suzuki, Satoshi Yoshihisa, Akiomi Yamaki, Takayoshi Nakazato, Kazuhiko Suzuki, Hitoshi Saitoh, Shu-ichi Kiko, Yuichirou Nakano, Hajime Hayashi, Takeharu Kimura, Akinori Takeishi, Yasuchika BMC Cardiovasc Disord Case Report BACKGROUND: Fabry disease is caused by mutations in the α-galactosidase A (GLA) gene, which is located in X-chromosome coding for the lysosomal enzyme of GLA. Among many gene mutations, E66Q mutation is under discussion for its pathogenicity because there is no clinical report showing pathological evidence of Fabry disease with E66Q mutation. CASE PRESENTATION: A 65-year-old Japanese female was referred to our hospital for chest discomfort on effort. Transthoracic echocardiography showed severe left ventricular (LV) hypertrophy with LV outflow obstruction. Maximum LV outflow pressure gradient was 87 mmHg, and Valsalva maneuver increased the pressure gradient up to 98 mmHg. According to medical interview, one of her younger sister and a nephew died suddenly at age 42 and 36, respectively. Another younger sister also presented LV hypertrophy with outflow obstruction. Maximum LV outflow pressure gradient was 100 mmHg, and the E66Q mutation was detected similar to the case. Endomyocardial biopsy specimens presented vacuolation of cardiomyocytes, in which zebra bodies were detected by electron microscopic examination. Although the enzymatic activity of GLA was within normal range, the c. 196G>C nucleotide change, which lead to the E66Q mutation of GLA gene, was detected. We initially diagnosed her as cardiac Fabry disease based on the findings of zebra body. However, immunostaining showed few deposition of globotriaosylceramide in left ventricular myocardium, and gene mutations in the disease genes for hypertrophic cardiomyopathy (HCM), MYBPC3 and MYH6, were detected. Although the pathogenicity of the E66Q mutation cannot be ruled out, hypertrophic obstructive cardiomyopathy (HOCM) was more reasonable to explain the pathophysiology in the case. CONCLUSIONS: This is the confusable case of HOCM with Fabry disease with the GLA E66Q mutation. We have to take into consideration the possibility that some patients with the E66Q mutation may have similar histological findings of Fabry disease, and should be examed the possibility for harboring gene mutations associated with HCM. BioMed Central 2016-05-10 /pmc/articles/PMC4862085/ /pubmed/27160240 http://dx.doi.org/10.1186/s12872-016-0262-y Text en © Oikawa et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Oikawa, Masayoshi Sakamoto, Nobuo Kobayashi, Atsushi Suzuki, Satoshi Yoshihisa, Akiomi Yamaki, Takayoshi Nakazato, Kazuhiko Suzuki, Hitoshi Saitoh, Shu-ichi Kiko, Yuichirou Nakano, Hajime Hayashi, Takeharu Kimura, Akinori Takeishi, Yasuchika Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body |
title | Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body |
title_full | Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body |
title_fullStr | Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body |
title_full_unstemmed | Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body |
title_short | Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body |
title_sort | familial hypertrophic obstructive cardiomyopathy with the gla e66q mutation and zebra body |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862085/ https://www.ncbi.nlm.nih.gov/pubmed/27160240 http://dx.doi.org/10.1186/s12872-016-0262-y |
work_keys_str_mv | AT oikawamasayoshi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT sakamotonobuo familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT kobayashiatsushi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT suzukisatoshi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT yoshihisaakiomi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT yamakitakayoshi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT nakazatokazuhiko familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT suzukihitoshi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT saitohshuichi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT kikoyuichirou familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT nakanohajime familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT hayashitakeharu familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT kimuraakinori familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody AT takeishiyasuchika familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody |